SCHEMBL1459710

SCHEMBL1459710

CCn1nc(-c2cccnc2)cc1-c1ccc2[nH]c(-c3c(F)cccc3F)cc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.41
MMP2 P08253 1/20 0.41
MMP13 P45452 1/20 0.41
MMP14 P50281 1/20 0.41
IDO1 P14902 1/20 0.37
VCP P55072 1/20 0.37
SYK P43405 1/20 0.37
CLK2 P49760 3/20 0.36
CLK3 P49761 3/20 0.36
DYRK1A Q13627 3/20 0.36
HTR2C P28335 2/20 0.36
CYP2E1 P05181 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2A6 P11509 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2B6 P20813 1/20 0.36
CYP2C19 P33261 1/20 0.36
F3 P13726 3/20 0.35
TBXAS1 P24557 1/20 0.35
BACE1 P56817 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1459931 0.94 MMP2 (0.38) CYP19A1MMP2MMP13MMP14IDO1
SCHEMBL1460078 0.90 FFAR1 (0.42) CYP19A1MMP2MMP13MMP14IDO1
SCHEMBL1459970 0.89 CSNK1D (0.36) MMP2MMP13MMP14HTR2C
SCHEMBL1460718 0.89 S1PR1 (0.37) CYP19A1IDO1HTR2C
SCHEMBL1460032 0.88 HTR2C (0.37) CYP19A1CLK2HTR2C
SCHEMBL1459773 0.87 CYP19A1 (0.43) CYP19A1MMP2MMP13MMP14SYK
SCHEMBL15020516 0.86 ORAI1 (0.41) CLK2CLK3DYRK1AHTR2CCYP2E1
SCHEMBL1459544 0.84 HTR2C (0.47) HTR2C
SCHEMBL1459934 0.83 MMP13 (0.43) CYP19A1MMP2MMP13MMP14IDO1
SCHEMBL1460201 0.83 MMP2 (0.41) CYP19A1MMP2MMP13MMP14VCP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2480529-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 EP claimed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 WO claimed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US claimed
EP-2480529-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 EP disclosed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 WO disclosed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 WO disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ORAI1, RYR2, CACNA1E CYP19A1 1576/4885MMP2 4541/4885MMP13 4585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.